|Mitochondrial reactive oxygen species enhance AMP-activated protein kinase activation in the endothelium of patients with coronary artery disease and diabetes.|
|Jump to Full Text|
|PMID: 23057846 Owner: NLM Status: MEDLINE|
|The aim of the present study was to determine whether the endothelial dysfunction associated with CAD (coronary artery disease) and T2D (Type 2 diabetes mellitus) is concomitant with elevated mtROS (mitochondrial reactive oxygen species) production in the endothelium and establish if this, in turn, regulates the activity of endothelial AMPK (AMP-activated protein kinase). We investigated endothelial function, mtROS production and AMPK activation in saphenous veins from patients with advanced CAD. Endothelium-dependent vasodilation was impaired in patients with CAD and T2D relative to those with CAD alone. Levels of mitochondrial H(2)O(2) and activity of AMPK were significantly elevated in primary HSVECs (human saphenous vein endothelial cells) from patients with CAD and T2D compared with those from patients with CAD alone. Incubation with the mitochondria-targeted antioxidant, MitoQ(10) significantly reduced AMPK activity in HSVECs from patients with CAD and T2D but not in cells from patients with CAD alone. Elevated mtROS production in the endothelium of patients with CAD and T2D increases AMPK activation, supporting a role for the kinase in defence against oxidative stress. Further investigation is required to determine whether pharmacological activators of AMPK will prove beneficial in the attenuation of endothelial dysfunction in patients with CAD and T2D.|
|Ruth M Mackenzie; Ian P Salt; William H Miller; Angela Logan; Hagar A Ibrahim; Andrea Degasperi; Jane A Dymott; Carlene A Hamilton; Michael P Murphy; Christian Delles; Anna F Dominiczak|
Related Documents :
|17557976 - Endothelial activation markers and their key regulators after restrictive bariatric sur...
16523426 - Il-10 genotype predicts serum levels of adhesion molecules, inflammation and atheroscle...
9812916 - Circulating cell adhesion molecules are correlated with ultrasound-based assessment of ...
9398806 - Increased levels of soluble adhesion molecules in the serum of patients with hepatitis ...
10397996 - In vitro evaluation of the inflammatory potential of the silk fibroin.
15140826 - Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blo...
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: Clinical science (London, England : 1979) Volume: 124 ISSN: 1470-8736 ISO Abbreviation: Clin. Sci. Publication Date: 2013 Mar|
|Created Date: 2012-11-29 Completed Date: 2013-01-28 Revised Date: 2014-11-05|
Medline Journal Info:
|Nlm Unique ID: 7905731 Medline TA: Clin Sci (Lond) Country: England|
|Languages: eng Pagination: 403-11 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
AMP-Activated Protein Kinases
Coronary Artery Disease / metabolism
Diabetes Mellitus, Type 2 / metabolism
Endothelium, Vascular / metabolism*
Mitochondria / metabolism
Reactive Oxygen Species / metabolism*
Vasodilation / physiology
|066780/2/012//Wellcome Trust; 11/0004309//Diabetes UK; MC_U105663142//Medical Research Council; RG/07/005/23633//British Heart Foundation|
|0/Reactive Oxygen Species; EC 126.96.36.199/AMP-Activated Protein Kinases|
Journal ID (nlm-ta): Clin Sci (Lond)
Journal ID (iso-abbrev): Clin. Sci
Journal ID (pmc): cls
Journal ID (publisher-id): CS
Publisher: Portland Press Ltd.
© 2013 The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY)(http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
Received Day: 9 Month: 5 Year: 2012
Revision Received Day: 11 Month: 10 Year: 2012
Accepted Day: 11 Month: 10 Year: 2012
epreprint publication date: Day: 11 Month: 10 Year: 2012
Electronic publication date: Day: 27 Month: 11 Year: 2012
Print publication date: Day: 1 Month: 3 Year: 2013
Volume: 124 Issue: Pt 6
First Page: 403 Last Page: 411
PubMed Id: 23057846
Publisher Id: CS20120239
|Mitochondrial reactive oxygen species enhance AMP-activated protein kinase activation in the endothelium of patients with coronary artery disease and diabetes Title for RRH:Mitochondrial ROS and AMPK in diabetes Alternate Title:R. M. Mackenzie and others|
|Ruth M. Mackenzie*|
|Ian P. Salt*|
|William H. Miller*|
|Hagar A. Ibrahim*|
|Jane A. Dymott*|
|Carlene A. Hamilton*|
|Michael P. Murphy†|
|Anna F. Dominiczak*|
|*Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, U.K.
|†MRC Mitochondrial Biology Unit, Cambridge, U.K.
|‡School of Computing Science, University of Glasgow, Glasgow, U.K.
|Correspondence: Correspondence: Dr Christian Delles (email Christian.Delles@glasgow.ac.uk).
The prevalence of CAD (coronary artery disease) in patients with diabetes is notably higher than in the general population. Up to a third of patients requiring coronary intervention have diabetes, and outcome is poorer in these patients than in patients without diabetes [1,2]. With the worldwide incidence and prevalence of diabetes increasing, more individuals will be affected by CAD and related complications and further pressure on health systems is expected . The relationship between diabetes and vascular disease is complex and multifactorial . Increased vascular oxidative stress has been proposed as a mechanism responsible for impaired endothelial function in patients with diabetes , but it is unknown whether these findings persist in the light of the more aggressive primary and secondary prevention strategies to which these vulnerable patients are subject .
Mitochondria are a major source of ROS (reactive oxygen species) production in the vasculature and contribute to oxidative stress and endothelial dysfunction in a range of cardiovascular pathologies, including CAD and T2D (Type 2 diabetes mellitus) [5,6]. However, mtROS (mitochondrial ROS) are also of importance in cellular signalling and, at low O2 concentrations, mitochondria of HUVECs (human umbilical vein endothelial cells) have been shown to generate ROS for activation of enzymes such as AMPK (AMP-activated protein kinase) .
Human AMPK is a heterotrimeric serine/threonine kinase, consisting of a catalytic α-subunit and regulatory β- and γ-subunits, each of which has two or more isoforms that are encoded by distinct genes and differentially expressed in various tissues . Involved in the regulation of cellular and whole body energy status , activation of AMPK requires phosphorylation at Thr172 by an AMPK kinase. Two AMPK kinases have been isolated to date, LKB1  and CaMKK (Ca2+/calmodulin-dependent kinase kinase) . It has been proposed that LKB1 activity is constitutive, such that stimuli which increase the AMP/ATP ratio, including hypoxia, hypoglycaemia and ischaemia, inhibit dephosphorylation at Thr172, permitting phosphorylation and activation of AMPK by LKB1 . In contrast, activation of AMPK by Ca2+ is AMP-independent and mediated by CaMKK [11,12]. More recently, AMPK activation via a ROS-mediated mechanism has been described [7,13–18].
Proposed as a candidate target for therapeutic intervention in endothelial dysfunction, AMPK stimulates eNOS (endothelial nitric oxide synthase), leading to NO production in cultured endothelial cells . Furthermore, stimulation of endothelial AMPK is reported to attenuate pro-inflammatory signalling [20,21] and there is accumulating evidence to suggest a role for the kinase in defence against oxidative stress in the endothelium [8,22,23].
The present study was designed to test the hypothesis that the endothelial dysfunction associated with CAD and T2D occurs in parallel with increased mtROS production in the endothelium and that this, in turn, regulates endothelial AMPK activity.
Detailed methods can be found in Supplementary Materials and methods section at http://www.clinsci.org/cs/124/cs1240403add.htm.
We recruited 79 volunteers with severe CAD from cardiothoracic pre-operative clinics. A blood sample was taken after 3 h of fasting on the day of admission for CABG (coronary artery bypass graft) surgery. Twenty three volunteers had a history of T2D. T2D was defined as having fasting venous blood glucose ≥6.1 mmol/l or ≥10 mmol/l 2 h post-oral glucose load (75 g). We also recruited 19 control volunteers free of evidence of CAD who were undergoing surgery for the removal of varicose veins. For these volunteers, a blood sample was taken following 3 h of fasting 1–2 weeks after surgery. The study complies with the Declaration of Helsinki and was approved by the local ethics committee. All participants gave written informed consent.
Surplus portions of freshly harvested saphenous veins from volunteers undergoing CABG surgery or elective varicose vein removal were stored in sterile saline solution. Maximum storage time was 2 h. Only non-varicosed portions of veins from control patients, as identified by the surgical team, were utilized. Samples were taken to the laboratory and cleaned of excess connective tissue. Endothelial cells were isolated from sections of samples on the day of surgery and the remainder of samples stored at 4°C in a Krebs Hepes buffer (118 mmol/l NaCl, 10 mmol/l Hepes/NaOH, pH 7.4, 25 mmol/l NaHCO3, 4.7 mmol/l KCl, 1.2 mmol/l MgSO4, 1.2 mmol/l KH2PO4, 11 mmol/l glucose, 10 μmol/l indomethacin and 50 μmol/l EDTA) for study of endothelial function the following day.
Rings (3 mm) of saphenous vein were studied in organ bath chambers as previously described . Vessels were constricted with phenylephrine (3 μmol/l) and relaxation in response to the calcium ionophore A23187 (0.01–10 μmol/l) was studied. Maximum relaxation was calculated and is expressed as a percentage of constriction in response to phenylephrine.
HSVECs (human saphenous vein endothelial cells) were isolated on the day of surgery by standard collagenase digestion based on a modified version of the protocol described by Jaffe et al. . Cells were cultured in complete Large Vessel Endothelial Cell Basal Medium (TCS Cellworks), supplemented with 20% (v/v) FBS (fetal bovine serum), 100 units/ml penicillin, 100 μg/ml streptomycin and 2 mmol/l L-glutamine. Cells were used at passage 3 and all experimental procedures were carried out when cells were about 80% confluent.
For immunofluorescent staining of vWF (von Willebrand factor), passage 3 HSVECs were harvested and plated onto sterile coverslips before being fixed in 4% (w/v) PFA (paraformaldehyde). Cells were then incubated with mouse anti-vWF primary antibody [1:50 dilution in 20% (v/v) goat serum/PBS] followed by goat-anti-(mouse IgG)–FITC-conjugated secondary antibody (1:200 dlution in 20% (v/v) goat serum/PBS; Dako). Coverslips were subsequently mounted in Vectashield (Vector Laboratories), containing propidium iodide for nucleic counter-staining, and cells visualized under a fluorescence microscope (Olympus BX40).
Measurement of HSVEC mitochondrial H2O2 production was carried out using the mitochondria-targeted H2O2 MS probe, MitoB, as described previously for cell culture experiments . Where required, HSVECs were incubated at 37°C in medium supplemented with 1 μmol/l MitoQ10 for 1 h prior to washing in PBS and incubation in medium supplemented with 5 μmol/l MitoB for 6 h.
Total RNA was extracted from HSVECs using the RNeasy® Mini Kit (QIAGEN) and quantified (NanoDrop ND-100 Spectrophotometer). cDNA was synthesized from 1 μg of DNase-treated (TURBO DNA-free™; Ambion) total RNA (TaqMan® Reverse Transcription Reagents; Applied Biosystems). Relative quantification of PRKAA1 (encoding the AMPK-α1 catalytic subunit) expression, relative to GAPDH (encoding glyceraldehyde-3-phosphate dehydrogenase), was calculated using the comparative (ΔΔCt) method .
HSVECs were serum-starved overnight before being incubated for 1 h at 37°C in Krebs Ringer Hepes buffer (119 mmol/l NaCl, 20 mmol/l Hepes, pH 7.4, 5 mmol/l NaHCO3, 4.7 mmol/l KCl, 1.3 mmol/l CaCl2, 1.2 mmol/l MgSO4, 1 mmol/l KH2PO4, 0.1 mmol/l L-arginine, 5 mmol/l glucose) in the presence of 1 μmol/l MitoQ10, 1 μmol/l DTPP (decyl triphenylphosphonium bromide) and 2 mmol/l AICAR (5-amino-4-imidazolecarboxamide riboside) where required. Cell lysates were prepared and AMPK immunoprecipitated and assayed using the SAMS peptide as previously described .
For clinical data and measurements in whole vessels, continuous data are given as means±S.D. or medians (interquartile range) unless otherwise indicated. Values stated are means±S.E.M. for cellular data. For comparisons of a continuous variable between two experimental groups, paired and unpaired Student's t test and Mann–Whitney U tests were applied as appropriate. For comparisons of a continuous variable in datasets with more than two groups, ANOVA was applied, followed by the Tukey's post-hoc test for all possible pairwise comparisons. Categorical data were analysed by Fisher's exact test. A P value of less than 0.05 (two-tailed) was considered significant.
Demographic and clinical characteristics of patients and control subjects are given in Table 1. As expected, patients with CAD were older and more likely to be on cardiovascular medication than control subjects. Total cholesterol and LDL (low-density lipoprotein)-cholesterol levels were lower in patients with CAD compared with control subjects, consistent with lipid-lowering therapy in the patient group. HDL (high-density lipoprotein)-cholesterol levels were significantly greater in control subjects compared with patients. Patients with T2D had a greater BMI (body mass index) and a greater percentage of HbA1c (glycated haemoglobin), but no other significant differences to patients without diabetes were observed. A total of ten out of the 23 patients with T2D (43%) were treated with metformin.
Endothelium-dependent relaxation was impaired in vessels of patients with CAD compared with those obtained from control subjects (maximum relaxation in response to A23187, 43±16 compared with 62±16%; P=0.001; Figures 1A and 1C). Patients with CAD and T2D had significantly reduced endothelium-dependent relaxation compared with those with CAD alone (maximum relaxation in response to A23187, 34±11 compared with 47±16%; P=0.008; Figures 1B and 1C). See Supplementary Figure S1 (at http://www.clinsci.org/cs/124/cs1240403add.htm) for data in saphenous veins concerning the vasorelaxation in response to carbachol and Supplementary Figures S1 and S2 (at http://www.clinsci.org/cs/124/cs1240403add.htm) for endothelium-dependence of the relaxation in response to carbachol and A23187.
It has been demonstrated that mtROS contribute to the oxidative stress and endothelial dysfunction characteristic of CVD (cardiovascular disease) [5,6]. To establish whether increased levels of mitochondrially produced H2O2 were concomitant with the endothelial dysfunction observed in vessels from patients with CAD, we investigated mitochondrial H2O2 production in primary HSVECs (Figure 2A) isolated from these patients and control subjects.
Significantly greater mitochondrial H2O2 production was noted in HSVECs from CAD patients with T2D relative to those from patients with CAD alone (MitoP/MitoB ratio, 0.054±0.003 compared with 0.042±0.003; P=0.02; Figure 2B). This finding was independent of mitochondria number (Supplementary Figure S3 at http://www.clinsci.org/cs/124/cs1240403add.htm). The mitochondrial-targeted antioxidant MitoQ10 had no significant effect on basal mitochondrial H2O2 production in HSVECs from patients with CAD alone (MitoP/MitoB ratio, 0.042±0.003 compared with 0.044±0.004; P=0.61; Figure 2B), patients with CAD and T2D (MitoP/MitoB ratio, 0.054±0.003 compared with 0.052±0.004; P=0.35; Figure 2B) and control subjects (MitoP/MitoB ratio, 0.043±0.006 compared with 0.045±0.003, P=0.58; Figure 2B).
AMPK has recently been implicated in attenuation of endothelial oxidative stress [8,22,23]. In addition, the kinase has been shown to be activated in response to a variety of ROS, including H2O2 [13,18,29].
As shown in Figure 3(A), activity of AMPK was increased in cells from CAD patients as compared with those from control subjects (0.045±0.007 compared with 0.022±0.006 nmol·min−1·mg−1; P=0.05). When compared with control subjects, a greater increase in AMPK activity was observed in HSVECs from patients with CAD and T2D (0.062±0.011 compared with 0.022±0.006 nmol·min−1·mg−1; P=0.01; Figure 3A) than in cells from patients with CAD alone (0.031±0.005 compared with 0.022±0.006 nmol·min−1·mg−1; P=0.26; Figure 3A). AMPK activity was significantly higher in HSVECs from patients with CAD and T2D than in those from patients with CAD alone (0.062±0.011 compared with 0.031±0.005; P=0.01; Figure 3A).
No change in the mRNA expression of PRKAA1, encoding the AMPK-α1 catalytic subunit, was observed between patient groups (Figure 3B), consistent with modulation of AMPK activity via post-translational modification. In addition, there was no significant difference in protein expression of AMPK-α1 (Supplementary Figure S4 at http://www.clinsci.org/cs/124/cs1240403add.htm) or the upstream AMPK kinase LKB1 (Supplementary Figure S5 at http://www.clinsci.org/cs/124/cs1240403add.htm), as assessed by immunoblotting.
Given the increased AMPK activity observed in HSVECs from patients with CAD and the poorer endothelial function of these subjects, phosphorylation of eNOS, an AMPK substrate, was investigated in cells from these CAD patients by means of immunoblotting (Figure 4A). Densitometric analysis revealed significantly lower basal eNOS phosphorylation in HSVECs from CAD patients with T2D (Figure 4B), despite the increased basal AMPK activity in these cells (Figure 3A). Incubation of HSVECs with AICAR, an artificial activator of AMPK , appeared to result in increased eNOS phosphorylation in cells from patients with CAD alone, although results were not significant (Figure 4B). However, AICAR treatment failed to stimulate eNOS phosphorylation in HSVECs from those CAD patients with T2D (Figure 4B).
Vascular endothelial cells have been reported to be highly glycolytic . In support of this, HSVEC ATP synthesis was largely the result of glycolysis, as assessed by the relative effects of 2DG (2-deoxy-D-glucose) and rotenone (Supplementary Figure S6 at http://www.clinsci.org/cs/124/cs1240403add.htm).
An alternative, potentially significant role for endothelial mitochondria is the generation of ROS for signalling purposes . The contribution of mtROS to AMPK activation was investigated by treating HSVECs from CAD patients with MitoQ10 and subsequently assaying AMPK activity. To control for non-specific effects of MitoQ10, cells were treated with the non-active control compound, DTPP . Exposing HSVECs to MitoQ10 resulted in a reduction in AMPK activity (Figure 5). The MitoQ10-mediated decrease in AMPK activity was greater in HSVECs from CAD patients with T2D (0.056±0.004 compared with 0.009±0.01 nmol·min−1·mg−1; P=0.02; Figure 5B) than in those from patients with CAD alone (0.035±0.005 compared with 0.014±0.0002 nmol·min−1·mg−1; P=0.06; Figure 5A).
Treating HSVECs from CAD patients with AICAR resulted in a significant increase in kinase activity in cells from patients with CAD alone (0.035±0.005 compared with 0.095±0.01 nmol·min−1·mg−1; P=0.05; Figure 5A).
Increased vascular oxidative stress has been proposed as one potential mechanism underlying endothelial dysfunction in patients with CAD and T2D . The present study involved investigation of endothelial function and molecular determinants of oxidative stress in human saphenous veins. Previous studies have demonstrated human arterial and venous levels of oxidative stress are closely related [32,33], such that results should not be affected by the choice of vessel. Herein we report impaired endothelium-dependent relaxation in vessels from patients with advanced CAD. Poorer endothelial function was observed in those CAD patients with the additional cardiovascular risk factor, T2D. To investigate the molecular basis for the impaired endothelium-dependent relaxation in vessels from patients with CAD and T2D, endothelial cells were isolated from vascular tissue. Endothelial dysfunction was observed to be maintained in culture with significantly lower levels of basal eNOS Ser1177 phosphorylation in cells from CAD patients with T2D as compared with those with CAD alone. As isolated cells were maintained in culture for several weeks prior to investigation, it seemed likely that the effects of pharmacological treatments (including metformin, a known activator of AMPK ) would be lost, allowing more accurate insight into molecular determinants of impaired endothelial function and potentially causative oxidative stress.
The mitochondrial electron transport chain has been identified as a major source of ROS in the vasculature, contributing to the oxidative stress and endothelial dysfunction characteristic of CAD and T2D [5,6]. As such, following isolation and characterization of HSVECs, we investigated cellular mitochondrial H2O2 production and observed an increase in cells from patients with CAD and T2D which was not due to an increase in mitochondria number. Known to induce endothelial dysfunction , increased levels of mitochondrially produced H2O2 may therefore have a causal role in the significantly impaired vasorelaxation of CAD patients with T2D.
Vascular endothelial cells are recognized as being highly glycolytic and we have confirmed this to be the case for HSVECs. A potential reason for the favouring of glycolysis by endothelial cells has been proposed by Quintero and co-workers , whereby mitochondria are not preferentially used bioenergetically in these cells, allowing them to function primarily in the generation of ROS for signalling purposes, resulting in activation of enzymes, including AMPK.
Traditionally associated with maintenance of cellular energy homoeostasis, it is well documented that AMPK is activated in response to the increased AMP/ATP ratio characteristic of hypoxic stress. With regard to endothelial AMPK specifically, phosphorylation of the kinase has been observed at low O2 concentrations in HUVECs but is undetectable at 21% O2 or ‘normoxia’ . However, it has been suggested that kinase activation at low O2 concentrations may occur via a mechanism that is independent of altered nucleotide levels but is mtROS-mediated [7,13]. Interestingly, we were able to assay AMPK activity in HSVECs isolated from patients with CAD and cultured under normoxic conditions, indicating CVD phenotype could be linked to enzyme activation. Indeed, at 21% O2, HSVEC AMPK activity was significantly greater in cells from patients with CAD relative to control subjects. On stratifying CAD patients according to the presence of T2D, we found AMPK activity to be significantly increased in the endothelium of patients with CAD and T2D as compared with that of patients with CAD alone, despite no change in AMPKα1 expression or difference in levels of the upstream AMPK kinase LKB1. Incubating HSVECs with AICAR, an artificial, ROS-independent activator of AMPK, known to stimulate the kinase in endothelial cells , resulted in a significant increase in AMPK activity in cells from patients with CAD alone but not in cells from those patients with CAD and T2D whose basal AMPK activity approached maximal levels.
Given the elevated mitochondrial H2O2 production in HSVECs from patients with CAD and T2D, in addition to the glycolytic nature of the cells, it seemed likely that enhanced endothelial AMPK activation was occurring in an mtROS-mediated manner in these patients. In order to test this hypothesis, we treated HSVECs isolated from CAD patients with the mitochondria-targeted antioxidant, MitoQ10, which has been shown to prevent oxidative damage in endothelial cells in vitro . Our findings demonstrated a significant decrease in AMPK activation on treatment with MitoQ10 in cells from those patients with T2D. The non-antioxidant control for MitoQ10, DTPP, had no effect on AMPK activity in a parallel experiment, indicating results can be attributed to the antioxidant action of MitoQ10 specifically. The same effect was not seen in cells from CAD patients without T2D.
Taken together, our findings indicate a novel, mtROS-mediated activation of AMPK in the endothelium of patients with CAD and T2D. In terms of mtROS likely to be involved in activation of the kinase, in concordance with results presented here, a role for H2O2 has been reported [13,18,29]. However, MitoQ10 does not act by directly lowering H2O2 production , confirmed via investigation of HSVEC mitochondrial H2O2 levels in the presence and absence of the antioxidant. Therefore the signal emanating from mitochondria and activating AMPK in the endothelium of patients with CAD and T2D is unlikely to be H2O2 itself, but rather a downstream radical with which MitoQ10 reacts. Such radicals include lipid peroxidation products, generated on oxidation of mitochondrial lipids by H2O2.
Recent studies suggest AMPK activation improves endothelial function by counteracting oxidative stress in the endothelium. Indeed, the kinase suppresses NADPH oxidase and ROS production in endothelial cells  and stimulates NO production by eNOS, inducing endothelium-dependent vasodilation . In addition, AMPK activation attenuates pro-inflammatory signalling and monocyte adhesion to the endothelium . Furthermore, metformin, known to exert a portion of its effect through AMPK, has been reported to decrease intracellular production of mtROS in aortic endothelial cells , while activation of AMPK has been observed to reduce hyperglycaemia-induced mtROS production by induction of the endogenous mitochondrial antioxidant, SOD2 (superoxide dismutase 2) in HUVECs . Similarly, Colombo and Moncada  have demonstrated that endothelial AMPKα1 is responsible for the expression of a number of genes involved in antioxidant defence, including SOD2.
Our observations that eNOS Ser1177 phosphorylation is significantly reduced in cells from CAD patients with T2D implies that elevated AMPK activity alone against a background of T2D is not sufficient to increase eNOS phosphorylation at this residue. It could perhaps be the case that a phosphatase is activated in these patients or that this additional CVD risk factor results in eNOS being regulated in an alternative manner, rendering it much more difficult to phosphorylate. Interestingly, AMPK has recently been shown to phosphorylate eNOS at the additional residue Ser633 and ablation of AMPKα2 was observed to be sufficient to inhibit atorvasatin-stimulated eNOS phosphorylation at both this residue and Ser1177, despite AMPKα1 being the principle isoform in terms of total cellular activity . Consequently, it is feasible that the increased AMPK activity observed in CAD patients with T2D reflects increased AMPKα1 activity alone and that AMPKα2 activity is required for eNOS Ser1177 phosphorylation. In accordance with our findings, Wang et al.  have reported that HUVECs subject to low glucose concentrations demonstrate reduced NO bioavailability associated with increased mtROS production and AMPK activation, yet this fails to stimulate eNOS phosphorylation.
In the endothelium of patients with CAD and T2D, AMPK may be part of a feedback or adaptive mechanism, wherein elevated mtROS production results in activation of AMPK which, in turn, stimulates protective responses which may contribute towards, but are not solely responsible for, increasing NO bioavailability and attenuating endothelial dysfunction. Although not investigated here, the mtROS-activated AMPK may also induce SOD2 activity, thus counteracting mitochondrial oxidative stress and generating H2O2 for further kinase activation and perpetuation of the cycle (Figure 6).
In summary, our results demonstrate elevated mtROS production in the endothelium of patients with CAD and T2D, suggesting mitochondria contribute to the more severe endothelial dysfunction observed in these patients. In addition, we have shown a novel, mtROS-mediated mechanism for AMPK activation in the endothelium of patients with CAD and T2D. Although this novel AMPK activation supports a role for the kinase in counteraction of oxidative stress, we demonstrate that increased AMPK activity does not simply translate to increased eNOS phosphorylation in these subjects and is therefore not sufficient to attenuate the more severe endothelial dysfunction characteristic of diabetic patients.
- • Increasing evidence exists to suggest that elevated mtROS production may contribute to poorer endothelial function in patients with CAD and T2D compared with patients without T2D.
- • In the present study, we have demonstrated significantly increased levels of mtROS in primary endothelial cells from patients with CAD and T2D and a concomitant increase in endothelial AMPK activity. This enhanced kinase activity is, however, insufficient to increase eNOS phosphorylation.
- • Further investigation is required to determine whether pharmacological activators of AMPK will prove benefical in attenuating endothelial dysfunction in patients with CAD and T2D.
Patients were recruited by Christian Delles and Jane Dymott. Ruth Mackenzie, Ian Salt, Hagar Ibrahim, William Miller, Angela Logan and Carlene Hamilton performed the experiments. All authors analysed and interpreted the data. The paper was drafted by Ruth Mackenzie, Ian Salt and Christian Delles, with critical input from all of the authors.
We thank Professor Salvador Moncada for help with investigating ATP production.
This work was supported by the British Heart Foundation [Chair Grant (to A.F.D.) and Programme Grant [RG/07/005/23633 (to A.F.D. and C.D.)]; the European Union's Sixth Framework Programme ‘InGenious HyperCare’ (to A.F.D. and C.D.) and Seventh Framework Programme ‘EU-MASCARA’ (to A.F.D. and C.D.); and the Wellcome Trust Cardiovascular Functional Genomics Initiative [grant number 066780/2/012 (to A.F.D.)].
|1.||Berry C.,Tardif J. C.,Bourassa M. G.. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularizationJ. Am. Coll. Cardiol.Year: 20074964365617291929|
|2.||Berry C.,Tardif J. C.,Bourassa M. G.. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive managementJ. Am. Coll. Cardiol.Year: 20074963164217291928|
|3.||Scrutinio D.,Giannuzzi P.. Comorbidity in patients undergoing coronary artery bypass graft surgery: impact on outcome and implications for cardiac rehabilitationEur. J. Cardiovasc. Prev. Rehabil.Year: 20081537938518677160|
|4.||Guzik T. J.,Mussa S.,Gastaldi D.,Sadowski J.,Ratnatunga C.,Pillai R.,Channon K. M.. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthaseCirculationYear: 20021051656166211940543|
|5.||Madamanchi N. R.,Runge M. S.. Mitochondrial dysfunction in atherosclerosisCirc. Res.Year: 200710046047317332437|
|6.||Nishikawa T.,Edelstein D.,Du X. L.,Yamagishi S.,Matsumura T.,Kaneda Y.,Yorek M. A.,Beebe D.,Oates P. J.,Hammes H. P.,et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damageNatureYear: 200040478779010783895|
|7.||Quintero M.,Colombo S. L.,Godfrey A.,Moncada S.. Mitochondria as signaling organelles in the vascular endotheliumProc. Natl. Acad. Sci. U.S.AYear: 20061035379538416565215|
|8.||Fisslthaler B.,Fleming I.. Activation and signaling by the AMP-activated protein kinase in endothelial cellsCirc. Res.Year: 200910511412719608989|
|9.||Hardie D. G.. AMPK: a key regulator of energy balance in the single cell and the whole organismInt. J. Obes.Year: 200832Suppl. 4S7S12|
|10.||Shaw R. J.,Kosmatka M.,Bardeesy N.,Hurley R. L.,Witters L. A.,DePinho R. A.,Cantley L. C.. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stressProc. Natl. Acad. Sci. U.S.AYear: 20041013329333514985505|
|11.||Hawley S. A.,Pan D. A.,Mustard K. J.,Ross L.,Bain J.,Edelman A. M.,Frenguelli B. G.,Hardie D. G.. Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinaseCell MetabYear: 2005291916054095|
|12.||Woods A.,Dickerson K.,Heath R.,Hong S. P.,Momcilovic M.,Johnstone S. R.,Carlson M.,Carling D.. Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cellsCell MetabYear: 20052213316054096|
|13.||Emerling B. M.,Weinberg F.,Snyder C.,Burgess Z.,Mutlu G. M.,Viollet B.,Budinger G. R.,Chandel N. S.. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratioFree Radical Biol. Med.Year: 2009461386139119268526|
|14.||Toyoda T.,Hayashi T.,Miyamoto L.,Yonemitsu S.,Nakano M.,Tanaka S.,Ebihara K.,Masuzaki H.,Hosoda K.,Inoue G.,et al. Possible involvement of the alpha1 isoform of 5′AMP-activated protein kinase in oxidative stress-stimulated glucose transport in skeletal muscleAm. J. Physiol. Endocrinol. MetabYear: 2004287E166E17315026306|
|15.||Zhang J.,Xie Z.,Dong Y.,Wang S.,Liu C.,Zou M. H.. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cellsJ. Biol. Chem.Year: 2008283274522746118693249|
|16.||Zou M. H.,Hou X. Y.,Shi C. M.,Kirkpatick S.,Liu F.,Goldman M. H.,Cohen R. A.. Activation of 5′-AMP-activated kinase is mediated through c-Src and phosphoinositide 3-kinase activity during hypoxia-reoxygenation of bovine aortic endothelial cells. Role of peroxynitriteJ. Biol. Chem.Year: 2003278340033401012824177|
|17.||Zou M. H.,Kirkpatrick S. S.,Davis B. J.,Nelson J. S.,Wiles W. G. IV,Schlattner U.,Neumann D.,Brownlee M.,Freeman M. B.,Goldman M. H.. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen speciesJ. Biol. Chem.Year: 2004279439404395115265871|
|18.||Zmijewski J. W.,Banerjee S.,Bae H.,Friggeri A.,Lazarowski E. R.,Abraham E.. Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinaseJ. Biol. Chem.Year: 2010285331543316420729205|
|19.||Morrow V. A.,Foufelle F.,Connell J. M.,Petrie J. R.,Gould G. W.,Salt I. P.. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cellsJ. Biol. Chem.Year: 2003278316293163912791703|
|20.||Ewart M. A.,Kohlhaas C. F.,Salt I. P.. Inhibition of tumor necrosis factor α-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinaseArterioscler. Thromb. Vasc. Biol.Year: 2008282255225718802013|
|21.||Hattori Y.,Suzuki K.,Hattori S.,Kasai K.. Metformin inhibits cytokine-induced nuclear factor κB activation via AMP-activated protein kinase activation in vascular endothelial cellsHypertensionYear: 2006471183118816636195|
|22.||Colombo S. L.,Moncada S.. AMPKalpha1 regulates the antioxidant status of vascular endothelial cellsBiochem. J.Year: 200942116316919442239|
|23.||Wang S.,Zhang M.,Liang B.,et al. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomesCirc. Res.Year: 20101061117112820167927|
|24.||Hamilton C. A.,Berg G.,McIntyre M.,Mcphaden A. R.,Reid J. L.,Dominiczak A. F.. Effects of nitric oxide and superoxide on relaxation in human artery and veinAtherosclerosisYear: 199713377869258410|
|25.||Jaffe E. A.,Nachman R. L.,Becker C. G.,Minick C. R.. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteriaJ. Clin. Invest.Year: 197352274527564355998|
|26.||Cocheme H. M.,Quin C.,McQuaker S. J.,Cabreiro F.,Logan A.,Prime T. A.,Abakumova I.,Patel J. V.,Fearnley I. M.,James A. M.,et al. Measurement of H2O2 within living drosophila during aging using a ratiometric mass spectrometry probe targeted to the mitochondrial matrixCell Metab.Year: 20111334035021356523|
|27.||Livak K. J.,Schmittgen T. D.. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt methodMethodsYear: 20012540240811846609|
|28.||Hardie D. G.,Haystead T. A. J.,Salt I. P.,Davies S. P.. Hardie D. G.Assay and purification of protein: serine/threonine kinasesProtein Phosphorylation: a Practical ApproachYear: 1999Oxford U.KOxford University Press201209|
|29.||Choi S. L.,Kim S. J.,Lee K. T.,Kim J.,Mu J.,Birnbaum M. J.,Soo Kim S.,Ha J.. The regulation of AMP-activated protein kinase by H2O2Biochem. Biophys. Res. Commun.Year: 2001287929711549258|
|30.||Corton J. M.,Gillespie J. G.,Hawley S. A.,Hardie D. G.. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?Eur. J. Biochem.Year: 19952295585657744080|
|31.||Ross M. F.,Prime T. A.,Abakumova I.,James A. M.,Porteous C. M.,Smith R. A.,Murphy M. P.. Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cellsBiochem. J.Year: 200841163364518294140|
|32.||Guzik T. J.,Sadowski J.,Kapelak B.,Jopek A.,Rudzinski P.,Pillai R.,Korbut R.,Channon K. M.. Systemic regulation of vascular NAD(P)H oxidase activity and NOX isoform expression in human arteries and veinsArterioscler. Thromb. Vasc. Biol.Year: 2004241614162015256399|
|33.||Berry C.,Hamilton C. A.,Brosnan M. J.,et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteriesCirculationYear: 20001012206221210801763|
|34.||Boulden B. M.,Widder J. D.,Allen J. C.,et al. Early determinants of H2O2-induced endothelial dysfunctionFree Radical Biol. Med.Year: 20064181081716895801|
|35.||Dhanasekaran A.,Kotamraju S.,Kalivendi S. V.,Matsunaga T.,Shang T.,Keszler A.,Joseph J.,Kalyanaraman B.. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosisJ. Biol. Chem.Year: 2004279375753758715220329|
|36.||James A. M.,Cocheme H. M.,Smith R. A.,Murphy M. P.. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental toolsJ. Biol. Chem.Year: 2005280212952131215788391|
|37.||Zhang Y.,Lee T. S.,Kolb E. M.,Sun K.,Lu X.,Sladek F. M.,Kassab G. S.,Garland T. Jr,Shyy J. Y.. AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stressArterioscler. Thromb. Vasc. Biol.Year: 2006261281128716601232|
|38.||Ouslimani N.,Peynet J.,Bonnefont-Rousselot D.,Therond P.,Legrand A.,Beaudeux J. L.. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cellsMetab., Clin. Exp.Year: 20055482983415931622|
|39.||Kukidome D.,Nishikawa T.,Sonoda K.,Imoto K.,Fujisawa K.,Yano M.,Motoshima H.,Taguchi T.,Matsumura T.,Araki E.. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cellsDiabetesYear: 20065512012716380484|
|40.||Chen Z.,Peng I. C.,Sun W.,Su M. I.,Hsu P. H.,Fu Y.,Zhu Y.,DeFea K.,Pan S.,Tsai M. D.,Shyy J. Y. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633Circ. Res.Year: 200910449650519131647|
|41.||Wang J.,Alexanian A.,Ying R.,Kizhakekuttu T. J.,Dharmashankar K.,Vasquez-Vivar J.,Gutterman D. D.,Widlansky M. E.. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinaseArterioscler. Thromb. Vasc. Biol.Year: 20123271272022207730|
Continuous data are given as means±S.D., irrespective of distribution or skewness. P values, however, derive from a Student's t test or Mann–Whitney U test as appropriate. Comparison between categorical data was performed using Fisher's exact test. SBP, systolic blood pressure; DBP, diastolic blood pressure; TAG, triacylglycerol; CRP, C-reactive protein; HbA1c, glycosylated haemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type I receptor blocker. *With T2D compared with Without T2D; †CAD compared with controls.
|Parameter||With T2D (n=23)||Without T2D (n=56)||P value*||Controls (n=19)||P value†|
|Sex (male/female) (n)||20/3||45/11||0.747||8/11||0.001|
|Total cholesterol (mmol/l)||3.95±1.10||4.11±0.99||0.542||4.96±0.99||0.029|
|Active smoking (yes/no) (n)||2/22||2/54||0.579||2/17||0.324|
|ACEI/ARB (yes/no) (n)||18/5||32/24||0.122||1/18||<0.001|
|Statin (yes/no) (n)||21/2||53/3||0.625||2/17||<0.001|
|Metformin (yes/no) (n)||10/13||0/56||<0.001||0/19||<0.001|
Keywords: AMP-activated protein kinase (AMPK), coronary artery disease (CAD), diabetes, endothelium, mitochondrion, oxidative stress.
Keywords: AICAR, 5-amino-4-imidazolecarboxamide riboside, AMPK, AMP-activated protein kinase, BMI, body mass index, CABG, coronary artery bypass graft, CAD, coronary artery disease, CaMKK, Ca2+/calmodulin-dependent kinase kinase, CVD, cardiovascular disease, 2DG, 2-deoxy-D-glucose, DTPP, decyl triphenylphosphonium bromide, eNOS, endothelial nitric oxide synthase, GAPDH, encoding glyceraldehyde-3-phosphate dehydrogenase, HbA1c, glycated haemoglobin, HDL, high-density lipoprotein, HSVEC, human saphenous vein endothelial cell, HUVEC, human umbilical vein endothelial cell, LDL, low-density lipoprotein, ROS, reactive oxygen species, mtROS, mitochondrial ROS, PRKAA1, encoding the AMPK-α1 catalytic subunit, SOD, superoxide dismutase, T2D, Type 2 diabetes, vWF, von Willebrand factor.
Previous Document: Mechanism of the plant cytochrome P450 for herbicide resistance: a modelling study.
Next Document: Prognostic significance of apical lymph node metastasis in patients with node-positive rectal cancer...